Genentech, Inc.

Janssen Pharmaceutica Nv

Liqiang Fu

Jun Liang

Steven Huy Do

Zhao-Kui Wan

Naomi S Rajapaksa

Marian C Bryan

James Richard Kiefer, Jr

Xuedong Dai

Tamiko Katsumoto

James Patrick Edwards

Patrick René Angibaud

Fei Wang

Virginie Sophie Poncelet

Olivier Alexis Georges Querolle

Wei Cai

Vineet Pande

Qian Liu

Kwong Wah Lai

Yimin Jiang

Joy Drobnick

Alberto Gobbi

Zhiguo Liu

Aaron Nathaniel Patrick

Daniel Jason Krosky

Yongsheng Chen

John Wai

Wing Shun Cheung

Yingtao Liu

Gang Deng

Barbara Morschhäuser Geb Herkert

Linglong Kong

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject, and the compound has the structure of Formula I including any possible deuterated isomers, stereoisomers or tautomeric forms thereof.

Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections

Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes. 

Exo-aza spiro inhibitors of menin-MLL interaction

Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

IRAK4 modulators

Growing community of inventors

Shanghai, China

Liqiang Fu